Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.89 |
| ▸ | BLM | P54132 | 4/20 | 0.87 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylatropine SCHEMBL56394 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL30003811 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL34463463 | 0.94 | CHRM2 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL824874 | 0.94 | CHRM2 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL29389879 | 0.93 | PABPC1 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL30647266 | 0.93 | BLM (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Methylatropine SCHEMBL1321572 | 0.93 | BLM (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Atropine Oxide SCHEMBL98985 | 0.87 | CYP2C19 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Atropine Oxide SCHEMBL29369999 | 0.87 | CYP2C19 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 | |
| Atropine Oxide SCHEMBL162929 | 0.87 | CYP2C19 (1.00) | SMN1; SMN2CHRM2BLMPABPC1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | Eagle Research Labs Limited (MT) | 2022-06-07 | — | — | US | disclosed |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200239455-A1 | DANTROLENE PRODRUGS AND METHODS OF THEIR USE | Eagle Research Labs Limited | 2020-07-30 | — | — | US | disclosed |
| EP-3678659-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | Eagle Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019050923-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239455-A1 | DANTROLENE PRODRUGS AND METHODS OF THEIR USE | BID, TPMT, CES2 | SMN1; SMN2 20/4885CHRM2 3600/4885BLM 1708/4885 |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | SMN1; SMN2 3/4885CHRM2 889/4885BLM 1246/4885 |
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | BID, TPMT, CES2 | SMN1; SMN2 20/4885CHRM2 3600/4885BLM 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.